Alnylam Pharmaceuticals, Inc.

Hoffmann-La Roche Inc.

Arrowhead Pharmaceuticals, Inc.

Arrowhead Madison, Inc.

Alnylam Europe Ag

Biosense Webster, Inc.

F. Hoffmann-La Roche Ag

Matthias John

Assaf Govari

Norbert Rahn

Stefan Limmer

Roland Kreutzer

Hans-Peter Vornlocher

Markus Hossbach

Jochen Deckert

Guy Georges

Philipp Hadwiger

Ulrich Brinkmann

Olaf Mundigl

Birgit Bramlage

Werner Scheuer

Assaf Preiss

Eike Hoffmann

Alexander Haas

Daniel J Chin

Rebecca Croasdale

Kerstin Jahn-Hofmann

Ludger Ickenstein

Jan Olaf Stracke

Silke Metz

Michael Grote

Wilma Dormeyer

Simone Dill

Claudia Woppmann

Christina Lorenz

Daniel Chin

Ludger Markus Ickenstein

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a Hepatitis B Virus gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Hepatitis B Virus infection using said pharmaceutical composition; and methods for inhibiting the expression of a Hepatitis B Virus gene in a cell.

Compositions and methods for inhibiting gene expression of hepatitis B virus

This invention relates to bispecific antibodies and antibody fragments against a target protein and a hapten, wherein the hapten is PEG or biotin, most preferably digoxigenin, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.

Bi-specific digoxigenin binding antibodies

The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a mutant gene, comprising a first strand that has a complementary region that is complementary to at least a portion of an RNA transcript of at least part of the mutant target gene and a second strand of the dsRNA complementary or substantially complementary to the first strand. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target mutant gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target mutant gene, as well as methods for treating diseases caused by the expression of the target gene.

Compositions and methods for inhibiting expression of a mutant gene

The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3'-untranslated region (3&#x2032;-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication.

Compositions and methods for inhibiting viral replication

The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a mutant gene, comprising a complementary RNA strand having a complementary region that is substantially complementary to a portion of the mutant gene, and which is partially complementary to the corresponding wild-type gene. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target mutant gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target mutant gene, as well as methods for treating diseases caused by the expression of the target gene.

The present invention relates to a method for the targeted selection of a double-stranded ribonucleic acid (dsRNA) consisting of two single strands that exhibits increased effectiveness in inhibiting the expression of a target gene by means of RNA interference, wherein at least end of the dsRNA comprises a nucleotide overhang of 1 to 4 unpaired nucleotides in length; wherein the unpaired nucleotide adjacent to the terminal nucleotide pair comprises a purine base; and wherein the terminal nucleotide pair on both ends of the dsRNA is a G-C pair, or at least two of the last four consecutive terminal nucleotide pairs are G-C pairs.

Double-stranded ribonucleic acid with increased effectiveness in an organism

Growing community of inventors

Hallstadt, Germany

Matthias John